Chikungunya virus gpE1 protein (A226V mutant) (30-1941)
Recombinant Chikungunya virus Glycoprotein E1 protein - A226V mutant
Overview
Overview
| Synonyms | Chikugunya virus Glycoprotein E1 A226V mutant, Mutant Chikugunya Glycoprotein E1 antigen, Chikugunya protein, A226V mutant Chikungunya protein, Chikungunya antigen, CHIKV protein |
|---|---|
| Species | Viral |
| Protein Type | Recombinant |
| Applications | ELISA, Lateral Flow, SDS-PAGE |
Specifications
| Expression System | Sf-9 insect cells |
|---|---|
| Method of Purification | Chikungunya Glycoprotein E1 A226V mutant antigen was purified by metal chromatography |
| Molecular Weight | 48 kDa |
| Tag/Conjugate | His tag |
| Form & Buffer | Supplied in liquid form in 50 mM Phosphate, pH 8 containing 300 mM NaCl and 10% glycerol |
Storage & Safety
| Storage | Aliquot and store at -70 deg C. Avoid repeated freeze thaw cycles. |
|---|
General Information
| Biological Significance | Chikungunya is a mosquito-borne viral disease first described during an outbreak in southern Tanzania in 1952. It is an alphavirus of the family Togaviridae. The name chikungunya derives from a root verb in the Kimakonde language, meaning "to become contorted" and describes the stooped appearance of sufferers with joint pain. |
|---|---|
| Implications in Disease | CHIKV infection causes an illness with symptoms similar to dengue fever, with an acute febrile phase of the illness lasting only two to five days, followed by a prolonged arthralgic disease that affects the joints of the extremities. The pain associated with CHIKV infection of the joints persists for weeks or months, or in some cases years. There is no vaccine to prevent or medicine to treat chikungunya virus infection. |
| Database Links | GenBank accession number CAJ90481.1 |
Reviews
You need to be logged in to write a review. Please login here
Sorry there are currently no reviews for this product